A Review on Formulation Development

Abstract

Formulation development is the scientific process of combining an active pharmaceutical ingredient (API) with inactive ingredients (excipients) to create a safe, stable, and effective patient dosage form.Drug formulation is the science of designing drug compositions that deliver active pharmaceutical ingredients safely and effectively. This discipline combines chemistry, biology, and engineering to optimize bioavailability, stability, and patient compliance, ensuring medications achieve their intended therapeutic outcomes while meeting regulatory standards.Drug formulation is an essential step in drug development, as it directly impacts the safety, efficacy, and patient experience of taking a drug. A well-crafted formulation ensures the APIs are delivered as intended, helping to optimize their therapeutic efficacy while minimizing side effects. Additionally, drug formulation helps to address practical concerns like patient compliance, making medications easier to administer, and increasing adherence to prescribing protocols. Additionally, it also plays a vital role in obtaining regulatory approval and patent protection, which underlines its significance in bringing new and improved therapies to market. In essence, the formulation process serves to bridge the gap between scientific breakthroughs and real-world applications, ultimately determining the impact of pharmaceutical interventions

Introduction

Pharmaceutical formulation development is the process of combining an Active Pharmaceutical Ingredient (API) with suitable inactive ingredients called excipients to produce a safe, effective, stable, and patient-friendly medicine. It connects drug discovery with the development of a commercially usable pharmaceutical product.

1. Objectives of Formulation Development

The main objectives are:

• Therapeutic efficacy: Ensure the medicine produces the desired therapeutic effect.

• Stability and shelf life: Protect the drug from degradation due to heat, light, and moisture.

• Bioavailability: Ensure the drug is absorbed into the body at the required rate and amount.

• Patient compliance: Develop convenient dosage forms with acceptable taste and ease of administration.

• Manufacturability: Ensure consistent and reliable production at industrial scale.

• Regulatory compliance: Meet required quality, safety, and efficacy standards.

2. Stages of Formulation Development

1. Pre-formulation studies: Analyze the API's solubility, particle size, polymorphism, stability, and compatibility with excipients.

2. Analytical method development: Develop testing methods to measure drug concentration, identify impurities, and assess product quality.

3. Excipient selection and dosage form design: Select suitable binders, fillers, disintegrants, and other excipients, and decide the dosage form.

4. Prototype formulation: Prepare and evaluate different small-scale formulations to identify suitable candidates.

5. Formulation optimization: Refine the composition and manufacturing process using techniques such as Quality by Design (QbD) and Design of Experiments (DoE).

6. Stability testing: Conduct accelerated and long-term studies to determine shelf life and storage conditions.

7. Scale-up and regulatory submission: Transfer laboratory processes to industrial production and compile quality, safety, and efficacy data for regulatory approval and clinical trials.

3. Common Pharmaceutical Dosage Forms

Formulations may also be designed for immediate or sustained drug release and targeted delivery.

4. Pre-formulation Studies

Pre-formulation studies are laboratory investigations of the physical and chemical properties of a drug substance and its interactions with excipients.

Their main objectives are to:

• Develop a stable, safe, and effective dosage form.

• Improve bioavailability and drug delivery.

• Establish the physicochemical characteristics of the API.

• Generate data for safe and commercially scalable manufacturing.

Important parameters include solubility, polymorphism, particle size, stability, and API–excipient compatibility.

5. Capsule Formulation and Manufacturing

5

Capsules are solid dosage forms in which drug substances and excipients are enclosed within soluble shells, generally made of gelatin.

Types of capsules

• Hard gelatin capsules: Two-piece shells consisting of a cap and body, generally used for powders and other suitable fills.

• Soft gelatin capsules: One-piece, hermetically sealed shells containing liquids, suspensions, or semisolids. They contain gelatin, plasticizers, and other ingredients.

Capsules are convenient to administer, tasteless, easy to carry, and useful for masking unpleasant drug tastes and odors. However, hygroscopic substances may make capsule shells brittle, and concentrated solutions may cause stomach irritation.

Manufacturing of hard gelatin capsules

1. Dipping: Stainless-steel pins are dipped into gelatin solution to form capsule caps and bodies.

2. Spinning: Pins are rotated to distribute gelatin uniformly.

3. Drying: Cool air and drying chambers remove moisture and harden the shells.

4. Stripping: Capsule shells are removed from the pins.

5. Trimming and joining: Shells are cut to the required length and cap and body are joined.

6. Polishing: Capsules are cleaned and polished to remove dust.

Capsule filling

The general steps are formulation preparation, capsule filling, sealing, and cleaning or polishing.

Common excipients include:

Capsules can be filled using hand-operated, semi-automatic, or automatic filling machines. They may be sealed by heat welding or gelatin solution.

6. Stability Testing and Process Optimization

• Accelerated stability testing uses elevated temperature and humidity to help predict stability and shelf life.

• Long-term stability testing evaluates the product under recommended storage conditions.

• Process scale-up transfers production from laboratory batches to commercial manufacturing while maintaining consistent quality.

• QbD helps identify and control critical quality attributes and manufacturing parameters.

7. Common Challenges

• Poor solubility: May reduce absorption; micronization and nanosuspensions are possible approaches.

• Stability problems: Heat, light, and moisture can degrade drugs. Antioxidants, coatings, and protective packaging may help.

• Taste and palatability: Taste-masking techniques improve acceptance, particularly in pediatric medicines.

• Regulatory requirements: Formulation and manufacturing must meet applicable quality and safety standards.

Conclusion

Formulation development\'s conclusion is that it is a critical, multifaceted process integral to pharmaceutical success, transforming active drug molecules into safe, effective, and patient-friendly treatments. Through meticulous design, testing, stability studies, and scale-up, it bridges the gap from concept to patient, influencing quality, efficacy, safety, and market viability. Advances in technology and a deep understanding of physicochemical properties are vital for overcoming challenges and ensuring successful, accessible, and innovative healthcare solutions. The formulation development studies along with the pre-formulation studies include the various tests, research & the S.O.P handling. These are the importantparameterofthepharmaceuticalindustrieswithoutthese pharmaceutical industriesdoes notconductproperlyandthequalityefficiency. Newproblems arise during development and it cannot be solve until required efforts with knowledgenot met. Formulation development\'s conclusion is that it is a critical, multifaceted process integral to pharmaceutical success, transforming active drug molecules into safe, effective, and patient-friendly treatments. Through meticulous design, testing, stability studies, and scale-up, it bridges the gap from concept to patient, influencing quality, efficacy, safety, and market viability. Advances in technology and a deep understanding of physicochemical properties are vital for overcoming challenges and ensuring successful, accessible, and innovative healthcare solutions

References

[1] Higginbotham, T.; Meier, K.; Ramírez, J.; Garaizar, A. (2025-02-03). \"Predicting Drug-Polymer Compatibility in Amorphous Solid Dispersions by MD Simulation: On the Trap of Solvation Free Energies\". Molecular Pharmaceutics. 22 (2): 760–770. doi:10.1021/acs.molpharmaceut.4c00810. ISSN 1543-8384. [2] Simler, R., Walsh, G., Mattaliano, R.J., Guziewicz, N., and Perez-Ramirez, B. (2008). Maximizing Data Collection and Analysis During Preformulation of Biotherapeutic Proteins. BioProcess International 6(10), 38-45. [3] Suarez, Adiran Garaizar; Göller, Andreas H.; Beck, Michael E.; Gheta, Sadra Kashef Ol; Meier, Katharina (2024-10-29). \"Comparative assessment of physics-based in silico methods to calculate relative solubilities\". Journal of Computer-Aided Molecular Design. 38 (1): 36. doi:10.1007/s10822-024-00576-y. ISSN 1573-4951. [4] M. Nocent, L. Bertocchi, F. Espitalier, M. Baron and G. Couarraze. (2001). Definition of a solvent system for spherical crystallization of salbutamol sulfate by quasi-emulsion solvent diffusion (QESD) method. Journal of Pharmaceutical Sciences 90 (10), 1620-1627. [5] \"Solventless mixing process for coating pharmaceutical ingredients\". Google Patents. 2013-10-09. Retrieved 2024-11-21. [6] Chang, B.S. and Hershenson, S. 2002. Practical approaches to protein formulation development. in \"Rationale Design of stable protein formulations-theory and practice\" (J.F. Carpenter and M.C. Manning eds.) Kluwer Academic/Plenum publishers, New York, pp. 1-25 [7] Garaizar, Adiran; Díaz-Oviedo, David; Zablowsky, Nina; Rissanen, Sami; Köbberling, Johannes; Sun, Jiawei; Steiger, Christoph; Steigemann, Patrick; Mann, Florian A.; Meier, Katharina (2024-11-05). \"Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments\". Proceedings of the National Academy of Sciences. 121 (45): e2404555121. doi:10.1073/pnas.2404555121. PMC 11551392. PMID 39475644. [8] Tse, Yincent; Dudley, Jan; Trivedi, Ashifa; Crook, Jo; Hawcutt, Daniel B.; Tomlin, Stephen (2025-06-01). \"Improving safety of unlicenced liquid specials medicines in the UK\". Archives of Disease in Childhood. 110 (6): 487–489. doi:10.1136/archdischild-2024-327558. ISSN 0003-9888. PMID 39227141. [9] Rationale Design of Stable Lyophilized Protein Formulations: Some Practical Advice, Carpenter et al, Pharmaceutical Research, Vol 14, No.8, 1977 [10] \"Doctor, why are you prescribing an ointment?\". American Academy of Dermatology [11] McMillanA,YoungH.ThetreatmentofPharyngealGonorrheawithasingleoraldoseofCefixime.IntJSTDAIDS.2007;18:253–4 [12] JournalofPharmaceuticalSciencesVolume74,Issue1,January1985,Pages16-20ResearchArticlesPreformulationStudiesina DrugDevelopment Programfor Tablet Formulations [13] TrevorM.Jones,CHAPTER1:PreformulationStudies,inPharmaceuticalFormulation:TheScienceandTechnologyofDosageForms,2018,pp.1-41DOI: [14] Sonali S Bharate&Ram A Vishwakarma impact of pre-formulation on drug development Pages 1239-1257 Published online:27 Mar2013 [15] Animportantapproachfornoveldrugdeliverysystemjournalofbiometricsciencepolymereditionbyheteshkumardevangen [16] Zhang L, Freeman LE, Nakamura J, Hecht SS, Vandenberg JJ, Smith MT, Sonawane BR. Formaldehyde and leukemia: epidemiology, potential mechanisms, and implications for risk assessment. Environ Mol Mutagen. 2010 Apr;51(3):181-91. [PMC free article] [PubMed] [17] Zhang L, Freeman LE, Nakamura J, Hecht SS, Vandenberg JJ, Smith MT, Sonawane BR. Formaldehyde and leukemia: epidemiology, potential mechanisms, and implications for risk assessment. Environ Mol Mutagen. 2010 Apr;51(3):181-91. [PMC free article] [PubMed] [18] Karpuzoglu E, Holladay SD, Gogal RM. Parabens: potential impact of low-affinity estrogen receptor binding chemicals on human health. J Toxicol Environ Health B Crit Rev. 2013;16(5):321-35. [PubMed [19] Khanna S, Dash PR, Darbre PD. Exposure to parabens at the concentration of maximal proliferative response increases migratory and invasive activity of human breast cancer cells in vitro. J Appl Toxicol. 2014 Sep;34(9):1051-9. [PubMed] [20] Karakaya G, Türe A, Ercan A, Öncül S, Aytemir MD. Synthesis, computational molecular docking analysis and effectiveness on tyrosinase inhibition of kojic acid derivatives. Bioorg Chem. 2019 Jul;88:102950. [PubMed] [21] Sosa-Hernández JE, Escobedo-Avellaneda Z, Iqbal HMN, Welti-Chanes J. State-of-the-Art Extraction Methodologies for Bioactive Compounds from Algal Biome to Meet Bio-Economy Challenges and Opportunities. Molecules. 2018 Nov 12;23(11) [PMC free article] [PubMed] [22] Levin J, Momin SB. How much do we really know about our favorite cosmeceutical ingredients? J Clin Aesthet Dermatol. 2010 Feb;3(2):22-41. [PMC free article] [PubMed] [23] Kligman D. Cosmeceuticals. Dermatol Clin. 2000 Oct;18(4):609-15. [PubMed] [24] Snake oil for the 21st century. Consum Rep. 2013 Nov;78(11):7. [PubMed] [25] Degim IT. New tools and approaches for predicting skin permeability. Drug Discov Today. 2006 Jun;11(11-12):517-23. [PubMed] [26] Raak C, Molsberger F, Pittermann W, Bertram M, Robens S, Ostermann T. Use of the Bovine Udder Skin model to evaluate the tolerability of Mesem cosmetic cream. Altern Lab Anim. 2017 Sep;45(4):191-200. [PubMed] [27] Rea H, Kirby B. A Review of Cutaneous Microdialysis of Inflammatory Dermatoses. Acta Derm Venereol. 2019 Oct 01;99(11):945-952. [PubMed] [28] Berardesca E, Loden M, Serup J, Masson P, Rodrigues LM. The revised EEMCO guidance for the in vivo measurement of water in the skin. Skin Res Technol. 2018 Aug;24(3):351-358. [PubMed] [29] Osseiran S, Cruz JD, Jeong S, Wang H, Fthenakis C, Evans CL. Characterizing stratum corneum structure, barrier function, and chemical content of human skin with coherent Raman scattering imaging. Biomed Opt Express. 2018 Dec 01;9(12):6425-6443. [PMC free article] [PubMed] [30] Rodrigues MM, Fontoura CP, Garcia CSC, Martins ST, Henriques JAP, Figueroa CA, Roesch-Ely M, Aguzzoli C. Investigation of plasma treatment on UHMWPE surfaces: Impact on physicochemical properties, sterilization and fibroblastic adhesion. Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:264-275. [PubMed] [31] Abdulhameed YA, Lancaster G, McClintock PVE, Stefanovska A. On the suitability of laser-Doppler flowmetry for capturing microvascular blood flow dynamics from darkly pigmented skin. Physiol Meas. 2019 Aug 02;40(7):074005. [PubMed] [32] Sonthalia S, Yumeen S, Kaliyadan F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Dermoscopy Overview and Extradiagnostic Applications. [PubMed] [33] Nomakhosi M, Heidi A. Natural options for management of melasma, a review. J Cosmet Laser Ther. 2018 Nov-Dec;20(7-8):470-481. [PubMed]

Copyright

Copyright © 2026 Badri Vishal Shukla, Pramod Mishra, Sujeet Pratap Singh, Dr. Tarkeshwar Prasad Shukla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.